Table 1.
Characteristics of included studies.
| References | Country | Design | Setting | Sepsis definition | SOFA scores | Patient characteristic | Age (median) | Male (%) | Sample | Assay | Outcome | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anand et al. (11) | India | PC | ICU | Sepsis-2 | 6 (4–8) | Sepsis | 56 | 61 | Serum | ELISA | Mortality/Septic shock | 7 |
| Beurskens et al. (31) | Netherland | PO | ICU | Sepsis-3 | 8 (7–11) | Sepsis | 67 | 43 | Plasma | ELISA | Mortality | 6 |
| Huang et al. (36) | China | PO | ICU | Sepsis-3 | 9.4 ± 3.8 | Sepsis | 66 | 82.2 | Plasma | ELISA | Septic shock/DIC | 6 |
| Ikeda et al. (38) |
Japan | PO | ICU | Sepsis-1 | 9 (5–12) | Sepsis | 73 | 66.7 | Serum | ELISA | DIC | 7 |
| Inkinen et al. (30) | Finland | PC | ICU | Sepsis-1 | 8 (6–10) | Sepsis and septic shock | 66 | 64 | Plasma | ELISA | Mortality/AKI | 7 |
| Johansen et al. (35) | Denmark | PO | ICU | Sepsis-1 | Not report | Sepsis | Not report | 55.4 | Serum | ELISA | Septic shock | 7 |
| Johansson et al. (34) | Denmark | PO | ICU | Sepsis-2 | 5 (5–7) | Severe sepsis | 66 | 59 | Serum | ELISA | Septic shock | 7 |
| Puskarich et al. (29) | USA | PC | ED | Sepsis-2 | 7 (4–9) | Severe sepsis | 61 | 53 | Plasma | ELISA | Mortality/AKI | 7 |
| Saoraya et al. (33) | Thailand | PO | ED | Sepsis-3 | 4.0 (2.0–6.0) | Sepsis | 76 | 62 | Plasma | ELISA | Mortality/Septic shock | 7 |
| Sexton et al. (32) | USA | PC | ICU | Sepsis-3 | 9.12 ± 3.96 | Sepsis and septic shouk | 52 | 55 | Plasma | ELISA | Mortality | 7 |
| Yu et al. (37) | USA | PC | ICU | Sepsis-2 | Not report | Severe sepsis | 55 | 51 | Plasma | ELISA | AKI | 6 |
PC, prospective cohort; PO, prospective observational; ICU, intensive care unit; ED, emergency department; SOFA, Sequential organ failure assessment score; DIC, disseminated intravascular coagulation; AKI, acute kidney injury; NOS, Newcastle-Ottawa Scale.